Home›Trial›NCT06788756
🔬NCT06788756Phase 2Phase 3RECRUITING

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Study Summary

This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into two parts, Part A and Part B.

Conditions
Acute Myeloid Leukaemia (AML)
Interventions / Drugs
Placebo in combination with Cytarabine InjectionLiposomal Annamycin Injection in combination with Cytarabine InjectionLiposomal Annamycin Injection in combination with Cytarabine InjectionLiposomal Annamycin for Injection in combination with Cytarabine Injection.
View on ClinicalTrials.gov ↗
Sponsor
MBRX
Moleculin Biotech
CNS Oncology
D37/100
Study Details
Enrollment312 participants
Primary Completion—
Lead SponsorMoleculin Biotech, Inc.
Data Retrieved2026-04-11 04:20:43.376396+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.